MacroGenics Q2 net income $19.5M; sells manufacturing to Bora for $122.5M, cash runway to 2028

MACROGENICS INC

Q2 2026 revenue $32.8M vs $6.9M YoY; net income $19.5M vs net loss $36.3M YoY, driven by $24.5M Sanofi TZIELD milestone and $89.2M discontinued ops gain.
Completed sale of GMP manufacturing to Bora for $122.5M base price; received $119.6M cash at closing; workforce cut to ~140 employees.
Pro forma cash $327M as of June 30, 2026 (incl. Bora, Sanofi, Gilead proceeds); cash runway guided through 2028.
Gilead exercised option for preclinical bispecific program, triggering $10.0M payment; eligible for up to ~$2.4B in future milestones from partners.
Pipeline: MGC026 SCCHN cohort met threshold to advance to Stage 2; MGC030 IND cleared, first patient Q3 2026; MGC028 update late 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.